SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 6, 2017
OptimizeRx Corporation
(Exact name of registrant as specified in its charter)
| Nevada | 000-53605 | 26-1265381 | ||
| (State
or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S.
Employer Identification No.) |
| 400 Water Street, Suite 200, Rochester, MI | 48307 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: 248.651.6568
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
SECTION 8 – Other Events
| Item 8.01 | Other Events |
On December 6, 2017, we issued a press release announcing a new initiative with Modernizing Medicine to help patients save money and be better educated about their prescriptions. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 8.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SECTION 9 – Financial Statements and Exhibits
| Item 9.01 | Financial Statements and Exhibits | |
| 99.1 | Press release, dated December 6, 2017 |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| OptimizeRx Corporation | |
| /s/ Douglas Baker | |
| Douglas Baker | |
| Chief Financial Officer | |
| Date: December 7, 2017 |
2
Exhibit 99.1
OptimizeRx
to Launch Real-time Financial Messaging With Modernizing
Medicine, Providing Prescription
Cost Savings at Point-of-Care
Rochester, MI, & Boca Raton, FL, (December 6, 2017) — OptimizeRx Corp. (OTCQB: OPRX), the nation’s leading provider of digital health messaging via electronic health record (EHR) systems, announces a new initiative with Modernizing Medicine to help patients save money and be better educated about their prescriptions.
Modernizing Medicine provides a specialty-specific, data-driven and cloud-based EHR system to dermatologists, ophthalmologists, orthopedic surgeons, plastic surgeons, urologists, otolaryngologists and pain management specialists nationwide. Over 10,000 providers use Modernizing Medicine’s mobile EHR system, EMA™, including more than 40 percent of U.S. dermatologists.
Modernizing Medicine’s EHR system was recently ranked #1 on the Black Book™ Physician Practice and Ambulatory Solutions list of top EHR systems for six specialties, and EMA has been named the #1 dermatology EHR system for four consecutive years.
OptimizeRx services will operate seamlessly within the Modernizing Medicine EHR system workflow to notify health care providers (HCPs) of potential prescription savings and support information for their patients.
“HCPs using our EHR system should be able to better address two of the greatest challenges in healthcare: improving affordability of medications and encouraging greater adherence,” said Dr. Michael Sherling, Chief Medical & Strategy Officer of Modernizing Medicine. “In this way Modernizing Medicine continues to serve our clients by providing additional technology intended to increase practice efficiency and improve patient outcomes.”
OptimizeRx’s growing EHR and eRx network now reaches more than 500,000 HCPs in the U.S., making it the healthcare industry’s largest point-of-prescribe network.
Miriam Paramore, president of OptimizeRx, commented: “As a leader in specialty-specific EHR systems for thousands of HCPs, and consistently named a top-ranked EHR vendor, Modernizing Medicine further strengthens our network where our financial and brand messaging are distributed. We look forward to delivering our services through the interface with Modernizing Medicine’s award-winning EHR systems.”
OptimizeRx recently reported record net revenue in the third quarter of 2017, up 74% as compared to the same year-ago quarter, which was driven by growth in financial and brand messaging by new and returning clients. OptimizeRx expects the additional channel partner to enhance its reach, thereby supporting additional revenue growth.
About Modernizing Medicine
Modernizing Medicine® and its affiliated companies are transforming how healthcare information is created, consumed and utilized in order to increase practice efficiency and improve patient outcomes. Our specialty-specific, data-driven and cloud-based electronic health records (EHR) and practice management (PM) systems, plus revenue cycle management (RCM) services, were built by a team including specialty physicians and practice management professionals. Our suite of products and services is designed to transform the clinical, financial and operational aspects of dermatology, gastroenterology, ophthalmology, orthopedics, otolaryngology, pain management, plastic surgery and urology practices. We also offer products designed specifically for ambulatory surgery centers. For more information, please visit www.modmed.com. Connect with Modernizing Medicine on our Blog, Facebook, LinkedIn and Twitter.
About OptimizeRx
OptimizeRx® (OTCQB: OPRX) is the nation’s leading provider of digital health messaging via electronic health records (EHRs), providing a direct channel for pharma companies to communicate with healthcare providers. The company’s cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information. The company’s network is comprised of leading EHR platforms like Allscripts, Amazing Charts and Quest, and provides more than half a million healthcare providers access to these benefits within their workflow at the point of care. For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com.
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
IOS is a trademark or registered trademark of Cisco in the U.S. and other countries and is used under license by Apple, Inc. iPad is a registered trademark of Apple, Inc.
For more information, contact:
Modernizing
Medicine
Tara Auclair
Tel (561) 880-2998 x1321
tara.auclair@modmed.com
www.modmed.com
Matter
Jessica Wolter
Tel (978) 518-4536
modmed@matternow.com
www.matternow.com
OptimizeRx Contact:
Doug Baker, CFO
Tel (248) 651-6568 x807
dbaker@optimizerx.com
Investor Relations Contact for OptimizeRx:
Ron Both, CMA
Tel (949) 432-7557
oprx@cma.team
2